Seebri Neohaler
Seebri Neohaler contains glycopyrrolate, an anticholinergic (bronchodilator) used to prevent bronchospasm in people with COPD. It works by enlarging the airways in the lungs to make breathing easier. It must be administered using the Neohaler inhalation device and should not be swallowed. It is not a rescue medication and will not treat an asthma or COPD attack that has already started.
Dosage by Body Weight
The standard adult dose is the inhalation of the contents of one 15.6 mcg capsule twice daily (once in the morning and once in the evening) using the Neohaler inhaler. Do not swallow the capsules. Safety and effectiveness in pediatric patients have not been established.
- Body Weight
- Below 5 kg
- Dose
- Not indicated
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness in pediatric patients have not been established. This medicine is intended for adult COPD maintenance treatment.
- Body Weight
- 5-7 kg
- Dose
- Not indicated
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness in pediatric patients have not been established. This medicine is intended for adult COPD maintenance treatment.
- Body Weight
- 8-10 kg
- Dose
- Not indicated
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness in pediatric patients have not been established. This medicine is intended for adult COPD maintenance treatment.
- Body Weight
- 11-15 kg
- Dose
- Not indicated
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness in pediatric patients have not been established. This medicine is intended for adult COPD maintenance treatment.
- Body Weight
- 16-20 kg
- Dose
- Not indicated
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness in pediatric patients have not been established. This medicine is intended for adult COPD maintenance treatment.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not indicated | N/A | Safety and effectiveness in pediatric patients have not been established. This medicine is intended for adult COPD maintenance treatment. |
| 5-7 kg | Not indicated | N/A | Safety and effectiveness in pediatric patients have not been established. This medicine is intended for adult COPD maintenance treatment. |
| 8-10 kg | Not indicated | N/A | Safety and effectiveness in pediatric patients have not been established. This medicine is intended for adult COPD maintenance treatment. |
| 11-15 kg | Not indicated | N/A | Safety and effectiveness in pediatric patients have not been established. This medicine is intended for adult COPD maintenance treatment. |
| 16-20 kg | Not indicated | N/A | Safety and effectiveness in pediatric patients have not been established. This medicine is intended for adult COPD maintenance treatment. |
Formulation
Purpose
Long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
Generic Name
GlycopyrrolateScheduled Drug
No. This medicine is generally not treated as a scheduled/prescription-only drug in common consumer references, but local rules may vary.